Correction: Overexpression of MEOX2 and TWIST1 is Associated with H3K27me3 Levels and Determines Lung Cancer Chemoresistance and Prognosis.

In Fig 4, the statistical significance indicators are missing. Please see the corrected Fig 4 here.

Fig 4

Analysis of the enrichment profile of H3K27me3, H3K27ac and H3K4me3 at the MEOX2 and TWIST1 promoters in NSCLC patients.

(A) H3K27me3 enrichment in the MEOX2 promoter sequence (**Mann-Whitney U test, p≤0.01, and F test, p≤0.0003) and (B) H3K27me3 enrichment in the TWIST1 promoter sequence in high survival patients as compared to patients with poor prognoses (***Mann-Whitney U test,p≤0.01, and unpaired t-test, p≤0.02). (C) H3K27ac enrichment in the promoter sequence of MEOX2 (no significant changes) and (D) H3K27ac enrichment in the promoter sequence of TWIST1 in high survival patients compared to patients with poor prognoses (no significant changes). (E) H3K4me3 enrichment in the MEOX2 promoter sequence (*F test, p≤0.02) and (F) the TWIST1 promoter sequence in high survival patients compared to patients with poor prognoses (***F test, p≤0.0006). Error bars represent mean with range.